Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 2/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20164154 | 0.84 | MAPT (0.46) | CTSLCTSB | |
| SCHEMBL20164153 | 0.84 | MAPT (0.46) | CTSLCTSB | |
| SCHEMBL20164194 | 0.83 | ALDH1A1 (0.42) | HDAC1 | |
| SCHEMBL28615828 | 0.78 | CARM1 (0.34) | KEAP1CARM1PRMT6HDAC1 | |
| SCHEMBL28615827 | 0.78 | CARM1 (0.34) | KEAP1CARM1PRMT6HDAC1 | |
| SCHEMBL5192274 | 0.77 | KEAP1 (0.49) | KEAP1P2RX7HDAC1CHRM4 | |
| SCHEMBL15938679 | 0.74 | TGM2 (0.43) | KEAP1HDAC1HDAC6 | |
| Trifluoroacetic Acid SCHEMBL18300904 | 0.71 | KEAP1 (0.42) | KEAP1P2RX7HDAC1NTRK1CHRM4 | |
| SCHEMBL17865486 | 0.70 | CES2 (0.44) | KEAP1 | |
| SCHEMBL20164169 | 0.70 | MEN1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310777-B1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10160750-B2 | Diamide macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | KEAP1 530/4885MMP2 302/4885CARM1 4408/4885 |
| US-10160750-B2 | Diamide macrocycles as factor XIa inhibitors | TFPI, TFPI2, F11 | KEAP1 530/4885MMP2 302/4885CARM1 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.